Literature DB >> 33771667

FXR in liver physiology: Multiple faces to regulate liver metabolism.

Katrin Panzitt1, Martin Wagner2.   

Abstract

The liver is the central metabolic hub which coordinates nutritional inputs and metabolic outputs. Food intake releases bile acids which can be sensed by the bile acid receptor FXR in the liver and the intestine. Hepatic and intestinal FXR coordinately regulate postprandial nutrient disposal in a network of interacting metabolic nuclear receptors. In this review we summarize and update the "classical roles" of FXR as a central integrator of the feeding state response, which orchestrates the metabolic processing of carbohydrates, lipids, proteins and bile acids. We also discuss more recent and less well studied FXR effects on amino acid, protein metabolism, autophagic turnover and inflammation. In addition, we summarize the recent understanding of how FXR signaling is affected by posttranslational modifications and by different FXR isoforms. These modifications and variations in FXR signaling might be considered when FXR is targeted pharmaceutically in clinical applications.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; Bile acids; FXR; Glucose homeostasis; Lipid metabolism

Mesh:

Substances:

Year:  2021        PMID: 33771667     DOI: 10.1016/j.bbadis.2021.166133

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  13 in total

Review 1.  Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.

Authors:  Ki Wung Chung; Ye Eun Cho; Seung-Jin Kim; Seonghwan Hwang
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 4.946

Review 2.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 3.  Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.

Authors:  Weinan Zhou; Sayeepriyadarshini Anakk
Journal:  Mol Cell Endocrinol       Date:  2022-03-15       Impact factor: 4.369

Review 4.  Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.

Authors:  Ting-Ying Jiao; Yuan-di Ma; Xiao-Zhen Guo; Yun-Fei Ye; Cen Xie
Journal:  Acta Pharmacol Sin       Date:  2022-02-25       Impact factor: 7.169

Review 5.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

Review 6.  Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.

Authors:  Rui Xue; Lianyong Su; Shengyi Lai; Yanyan Wang; Derrick Zhao; Jiangao Fan; Weidong Chen; Phillip B Hylemon; Huiping Zhou
Journal:  Cells       Date:  2021-10-20       Impact factor: 7.666

7.  miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer.

Authors:  Xiaobo Nie; Huiyang Liu; Xiaoyun Wei; Lanqing Li; Linhua Lan; Lili Fan; Han Ma; Lei Liu; Yun Zhou; Ruifang Hou; Wei-Dong Chen
Journal:  Cancer Manag Res       Date:  2021-10-22       Impact factor: 3.989

Review 8.  New Kids on the Block: Bile Salt Conjugates of Microbial Origin.

Authors:  Ümran Ay; Martin Leníček; Arno Classen; Steven W M Olde Damink; Carsten Bolm; Frank G Schaap
Journal:  Metabolites       Date:  2022-02-13

Review 9.  Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.

Authors:  Veronika A Prikhodko; Natalia N Bezborodkina; Sergey V Okovityi
Journal:  Biomedicines       Date:  2022-01-26

Review 10.  Transcriptional Regulation of Hepatic Autophagy by Nuclear Receptors.

Authors:  Eun Young Kim; Jae Man Lee
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.